Home › Trials › NCT06871176
Clinical trial Recruiting at 1 site Interventional Ages 18 and up

PET/MR with a CXCR4 tracer versus standard PET/CT and MRI for initial staging and follow-up in multiple myeloma

Official title: [68Ga]Ga-PentixaFor (CXCR4) PET/MR for Initial Staging and Follow up in Multiple Myeloma: Prospective Comparison With Standard of Care PET/CT and Evaluation of Therapy Influence

Run by University Health Network, Toronto · NCT06871176 · Data updated 2026-11-12

This test will see if a PET/MR scan using a new tracer called [68Ga]Ga-PentixaFor finds multiple myeloma in bones more accurately than standard PET/CT and MRI for adults at diagnosis or follow-up.

More Multiple Myeloma trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorUniversity Health Network, Toronto
Academic / other
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedApril 22, 2025
Main results expectedMarch 4, 2028
Study endsMarch 4, 2028
Registry record updatedOctober 1, 2026
Trial IDNCT06871176 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with a clinical diagnosis of multiple myeloma—including nonsecretory, oligosecretory, or suspected extramedullary disease—who are newly diagnosed or undergoing staging/follow-up and can tolerate MRI and PET/CT are ideal candidates.

Probably not a fit

Patients who are pregnant or breastfeeding, unable to lie still for imaging, have contraindications to MRI or PET/CT or known allergy to the tracer components, or have another active hematologic malignancy are unlikely to be eligible or to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares a combined PET/MR scan using the CXCR4-targeted tracer [68Ga]Ga-PentixaFor to standard 18F-FDG PET/CT and conventional MRI in people with multiple myeloma. Participants (adults, newly diagnosed or being evaluated around stem cell transplantation) will undergo both imaging approaches for initial staging and follow-up. Investigators will compare lesion detection, diagnostic accuracy, prognostic information, and the frequency with which imaging influences treatment decisions. The aim is to see whether CXCR4 PET/MR gives more precise disease mapping and could reduce the need for multiple separate imaging sessions.

Why it matters

Potential benefit: If successful, this imaging approach could detect bone and extramedullary myeloma more precisely, improve staging and treatment planning, and reduce the number of separate scans patients need.

How similar studies have gone: CXCR4-targeted PET imaging such as [68Ga]Ga-PentixaFor is a relatively new but promising approach with preliminary studies showing improved lesion detection in some myeloma patients, though it is not yet as widely validated as 18F-FDG PET/CT.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion criteria

* Patient older than 18 years of age
* Clinical diagnosis of (nonsecretory, oligosecretory, suspicion for extramedullary MM) MM. MM diagnosis is based on IMWG (International Myeloma Working Group) criteria.No treatment received beyond first course of

Exclusion criteria

* Any contra-indications for MRI or 18F-FDG PET/CT imaging according to institutional guideline
* Pregnancy (will be ruled out as per institutional protocol)
* Inability to lie still in prone position in MRI for at least 30 min or PET/CT for at least 30 min
* Patients or unwilling to use contraception during study and breastfeeding women can also not partake in this study
* Inability to provide consent
* Any hypersensitivity or known allergy to any component of the investigational product (\[68Ga\]Ga-PentixaFor)No concomitant other malignant hemato-oncological disease being diagnosed (i.e. additional lymphoma or leukemia)

Where it's running

  • University Health Network
    Toronto, Ontario, Canada     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Multiple Myeloma 458University Health Network, Toronto 216
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.